Open AccessExebacase Is Active In Vitro in Pulmonary Surfactant and Is Efficacious Alone and Synergistic with Daptomycin in a Mouse Model of Lethal Staphylococcus aureus Lung Infection
Author(s) -
Steven M. Swift,
Karen Sauve,
Cara Cassino,
Raymond Schuch
Publication year - 2021
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.02723-20
Subject(s) - daptomycin , staphylococcus aureus , microbiology and biotechnology , methicillin resistant staphylococcus aureus , antibiotics , pneumonia , in vivo , staphylococcal infections , medicine , minimum inhibitory concentration , vancomycin , biology , bacteria , genetics
Exebacase (CF-301) is a novel antistaphylococcal lysin (cell wall hydrolase) in phase 3 of clinical development for the treatment ofStaphylococcus aureus bacteremia, including right-sided endocarditis, used in addition to standard-of-care antibiotics. In the current study, the potential for exebacase to treatS. aureus pneumonia was exploredin vitro using bovine pulmonary surfactant (Survanta) andin vivo using a lethal murine pneumonia model.